Loading organizations...
§ Venture Capital · Washington, DC, USA
Venture capital firm investing in life sciences, biotechnology, therapeutics, medical devices, and pharmaceuticals.
Avoro Ventures is a New York-based venture capital firm focused on investing in early-stage and clinical-stage life sciences, biotechnology, and healthcare companies. Operating as the venture capital arm of Avoro Capital Advisors, the firm manages an inaugural fund that closed with $186 million in capital commitments in April 2022. The broader parent organization operates with 19 staff members and oversees approximately $5 billion to $6 billion in total assets under management. The firm provides capital to private and public therapeutic developers, building a portfolio that includes Apellis Pharmaceuticals, Cytokinetics, Carmot Therapeutics, Alumis, and RayzeBio. Recent liquidity events include the acquisition of portfolio company Carmot Therapeutics by Roche for up to $3.1 billion in December 2023. Avoro Ventures was established in 2019 by founder and managing partner Behzad Aghazadeh following a spin-out from venBio Select Advisor.
Key people at Avoro Ventures.
Avoro Ventures has 22 tracked investments across 11 companies. The latest tracked deal is $5.0M Seed in Cellvie in September 2025.
Key people at Avoro Ventures.
Avoro Ventures is a global venture capital firm specializing in investments within the life sciences sector, particularly biotechnology and specialty therapeutics. Its mission centers on supporting emerging biotech companies that pursue scientific breakthroughs to address unmet medical needs. The firm adopts a comprehensive investment philosophy that combines intellectual curiosity with rigorous risk management, aiming to identify unique or mispriced opportunities and provide financial and strategic support throughout the investment lifecycle. Avoro Ventures primarily focuses on late-stage private and publicly traded biotech companies, contributing significantly to the advancement of novel therapies and innovation in healthcare[1][2][4].
Avoro Ventures is affiliated with Avoro Capital Advisors, which was founded in 2010 and is headquartered in New York City. The firm’s leadership includes experienced investment partners such as Mark Chin and Uya Chuluunbaatar, who bring extensive backgrounds in healthcare venture capital, strategy consulting, and corporate development within biotech and pharmaceutical industries. The firm evolved from a hedge fund management background with a strong scientific and healthcare focus, expanding its scope to support both private and public biotech companies with strategic assets. This evolution reflects a commitment to bridging financial expertise with deep sector knowledge to foster innovation in life sciences[3][5][6].
Avoro Ventures operates at the intersection of biotechnology innovation and capital markets, riding the trend of increased investment in life sciences driven by advances in genomics, specialty therapeutics, and unmet medical needs. The timing is favorable due to growing demand for novel therapies and the maturation of biotech companies ready for late-stage funding or public market entry. Market forces such as regulatory support, technological breakthroughs, and heightened investor interest in healthcare innovation work in Avoro’s favor. By backing companies that push scientific boundaries, Avoro Ventures influences the broader ecosystem by accelerating the development and commercialization of transformative medical treatments[1][2][4].
Looking ahead, Avoro Ventures is poised to deepen its impact by continuing to identify and support high-potential biotech firms at critical growth stages. Trends shaping its journey include the rise of precision medicine, cell and gene therapies, and digital health integration. As the life sciences sector evolves, Avoro’s blend of financial acumen and scientific expertise will likely enhance its ability to navigate complex risks and capitalize on emerging opportunities. Its influence is expected to grow as it helps translate cutting-edge science into viable therapies, thereby contributing to improved patient outcomes and advancing the biotech investment landscape[1][3][5].
